Chris Kryder, MD
Chris Kryder, MD founded D2Hawkeye in 2000 and was CEO until early 2009, when he sold his firm to ISO, merging health care Information technology assets to form Verisk Health. ISO companies went public as Verisk Analytics (NASDAQ:VRSK) in late 2009. He remained CEO of Verisk Health until 1/1/11. Verisk Health, nee D2Hawkeye, provides healthcare data analytics and predictive modeling services to large medical groups, health plans, and employers. The company's products are used to manage clinical and financial risk. In 2008, Dr. Kryder co-founded Generation Health. GH is the first 'GBM' (Genetic-testing Benefits Manager), and is focused exclusively on genomics and personalized medicine. GH was sold to CVS Caremark in early 2010. Dr. Kryder received his B.A. from the University of Buffalo, his M.D. from Georgetown University, and his MBA from the Massachusetts Institute of Technology. He completed his internal medicine (primary care) medical residency at Harvard, and maintained his primary care medical practice at MIT until the late 1990s. He has been active on the faculty of Harvard Medical School, Division of Health, Science, and Technology for over twenty-five years. Dr. Kryder is Chairman of Valence Health, a growth stage 'clinical integration' software and health plan services firm. He is currently a member of the board of Tufts Medical Center in Boston. He is also an investor and board member of several early-stage firms engaged in healthcare services, IT, and biotechnology; he also provides adviory services to health care investors. His healthcare interests extend to South Asia and China; he has built large off-shore software operations in the former, and is currently investigating investment and healthcare IT opportunities in the latter.